Stavrianopoulos et al., U.S. Pat. Appl. Ser. No. 08/486,070 (Filed June 7, 1995)
Page 42 [Supplemental Amendment To Applicants' November 2, 2005
Amendment Under 37 C.F.R. §1.116]
-- November 8, 2005]

REMARKS

The paper follows a telephone call on November 4, 2005 between Primary Examiner John Brusca, Group Art Unit 1631, and Applicants' undersigned attorney. During the November 4th call, Examiner Brusca indicated that information was required with respect to Applicants' claim for priority and the abstract.

In response to the call, Applicants are providing a new clean version replacement Page 1 as Exhibit A which contains the priority information for this application.³ A marked-up version of Page 1 is also provided in Exhibit A. Replacement Page 1 (Exhibit A) contains the same priority information that was provided in Applicants' March 7, 2001 Amendment Under 37 C.F.R. §1.115. A copy of page 2 from their March 7, 2001 Amendment containing this same information is also provided in Exhibit B.

Also provided in Exhibit C is a new Abstract Of The Disclosure that is believed to conform with the requirements of 37 C.F.R. §1.72 and MPEP §608.01(b). Although abstracts were previously submitted in this application with the last one apparently having been filed in Applicants' October 31, 2003 Amendment, it is believed that this new Abstract (Exhibit C) is a more adequate and clearer statement of the contents of the disclosure, as set forth in MPEP §608.01(b).

Entry of new replacement page 1 (Exhibit A) and the new Abstract Of The Disclosure (Exhibit C) is respectfully requested.

Finally, the entry of a new shorter title has been requested above. This new title is reflected in the new Abstract (Exhibit C).

³ The present application claims priority of U.S. Patent Application Serial No. 06/461,469, filed on January 21, 1983.

NOV. 8. 2005 5:00PM ENZO BIOCHEM NO. 7160 P. 44

Stavrianopoulos et al., U.S. Pat. Appl. Ser. No. 08/486,070 (Filed June 7, 1995)
Page 43 [Supplemental Amendment To Applicants' November 2, 2005
Amendment Under 37 C.F.R. §1.116]
-- November 8, 2005]

No claims have been amended. For the sake of completeness, however, the status of the claims is as follows:

Claims presently presented: Claims 3144-3147, 3150-3155, 3157-3169,

3172-3175, 3179-3183, 3185-3201, 3204-3209,

3211-3224, 3227-3232, 3234-3238, 3240-3248, 3252-3256, 3258-3268, 3271-3277, 3279-3283

and 3287-3407.

Claims currently amended: No

None.

Claims currently canceled:

None.

Claims previously canceled:

Claims 1-3143, 3148-3149, 3156, 3170-3171,

3176-3178, 3184, 3202-3203, 3210, 3225-

3226, 3233, 3239, 3249-3251, 3257, 3269-

3270, 3278 and 3284-3286.

Claims currently added:

None.

Favorable and action is respectfully requested.

* * * * * *

Stavrianopoulos et al., U.S. Pat. Appl. Ser. No. 08/486,070 (Filed June 7, 1995)
Page 44 [Supplemental Amendment To Applicants' November 2, 2005
Amendment Under 37 C.F.R. §1.116]
- November 8, 2005]

SUMMARY AND CONCLUSIONS

No claims have been amended, canceled or added by this paper. New replacement Page 1 (Exhibit A) and a new Abstract Of The Disclosure (Exhibit C) have been provided for entry in this application.

This paper (Supplemental Amendment) is being timely filed. Thus, no extension request or fee is necessary. No other fee or fees are believed to be due in connection with this paper. In the event that any other fee or fees are due, however, The Patent and Trademark Office is hereby authorized to charge the amount of any such fee(s) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully gubmitted,

Ronald C. Fedus

Registration No. 32,567

Natalie Bogdanos

Registration No. 51,480 Attorney for Applicants

ENZO LIFE SCIENCES, INC. c/o ENZO BIOCHEM, INC. 527 Madison Avenue, 9th Floor New York, NY 10022-4304 Telephone: (212) 583-0100 Faosimile: (212) 583-0150